Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. and Vertex Pharmaceuticals Incorporated announced a strategic partnership to develop and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera will lead discovery using its proprietary TCE platform, while Vertex will fund all research and development and retain commercialization rights.

The deal involves an upfront payment of $28 million from Vertex, with additional payments contingent on preclinical, regulatory, and commercial milestones, as well as tiered royalties on net sales. This collaboration highlights the significant financial differences between the two companies. Vertex reported $3.33 billion in total revenues for Q2 2026, up 12% year-over-year, along with a net income of $1.1 billion.

The company is benefiting from its dominant cystic fibrosis (CF) portfolio and new therapies like CASGEVY and JOURNAVX, and has raised its full-year 2026 revenue guidance to $13.1 billion to $13.2 billion. In contrast, AbCellera is a clinical-stage entity that relies on partnerships for survival. Its Q2 2026 revenue fell to $4.1 million, down from $17.1 million a year earlier, and its net loss widened to $55.4 million.

However, AbCellera is gaining momentum with positive Phase 2 trial results for ABCL635, a non-hormonal treatment for menopausal hot flashes. The Phase 2 portion met its primary efficacy endpoints, leading to an upgrade of AbCellera's price target from $13 to $25 by JonesResearch. Despite a slight decrease in hedge fund support for AbCellera, institutional investors are still adjusting their exposure to both companies.

While Vertex offers proven commercial dominance and steady profitability, AbCellera is a high-risk, high-reward platform developer with potential for transformation if its clinical trials succeed.